跳到正文
原文
Nature 健康护理主题·· 4 天前AI 评分45

Alliance A061402 III 期结果:伊沙佐米联合来那度胺和地塞米松用于骨孤立性浆细胞瘤

Solitary plasmacytoma of bone (SPB): observations from a randomized phase III trial that evaluated the additional of adjuvant systemic treatment to zoledronic acid (ZA) after definitive radiation (alliance A061402)

AI 导读

一项III期试验(Alliance A061402)评估了伊沙佐米联合来那度胺和地塞米松作为骨孤立性浆细胞瘤(SPB)辅助治疗的效果。该试验因入组不足提前终止,共纳入10%的计划患者。主要终点为无进展至多发性骨髓瘤的时间(TTP-MM),结果显示该方案未能显著延长TTP-MM。

正文

Introduction

Solitary plasmacytoma of bone (SPB) is a localized tumor in the bone comprised of clonal plasma cells in the absence of other diagnostic features of multiple myeloma (MM), though patients may present with <10% clonal plasma cells in the bone marrow [1]. Most patients with SPB eventually develop overt MM, and numerous factors are associated with a shorter time to progression to active MM, including the presence of high-risk cytogenetics, abnormal serum free light chain ratio, minimal marrow involvement, and high-grade angiogenesis within the plasmacytoma [2,3,4,5].

Localized radiation therapy (RT), given at a dose of 40–50 Gy over approximately four weeks, is the current standard of care (SOC) treatment for SPB, although there have been no randomized trials assessing RT for patients with SPB [6]. Adjuvant chemotherapy (adjCT) after RT is controversial with some studies [7, 8] reporting no significant benefit and others concluding adjCT prolongs time to progression to MM (TTP-MM) [9]. As such, there is currently no consensus approach for patients with SPB with or without minimal (<10%) clonal plasma cells in the bone marrow (BM).

There is paucity of data with systemic clonal plasma cell-directed therapies in patients with SPB. In vitro data indicate synergistic tumoricidal activity between the proteosome inhibitor (PI), bortezomib, and lenalidomide (LEN), an immunomodulatory drug [10]. Ixazomib (IXA), an oral PI, appears to have a lower risk of neuropathy than bortezomib [11, 12]. Addition of IXA to a regimen of LEN and dexamethasone (DEX) is associated with a clinically meaningful improvement in PFS in transplant ineligible patients with newly diagnosed MM [13] and significantly longer PFS in patients with relapsed or refractory MM [14]. The MRC Myeloma IX trial evaluated ZA versus clodronic acid (clodronate) in newly diagnosed transplant and non-transplant candidates and showed that ZA decreased skeletal events and prolonged OS [15].

Given the established efficacy and safety of LEN combined with IXA and DEX, we conducted an adjuvant Phase III trial assessing whether the addition of LEN + IXA + DEX to ZA increases TTP-MM. Alliance for Clinical Trials in Oncology A061402, NCT02516423.

Materials/subjects and methods

The trial included a pre-registration component that allowed individuals ≥18 years with ECOG Performance Score 0–2 to pre-register prior to starting or after completion of RT if RT was scheduled to begin or began at most 28 days after a BM aspirate and biopsy were performed containing <10% clonal plasma cells, respectively. Pre-registered patients were registered to the trial if the following eligibility were met: measurable disease (see Supplementary Table 1), no lytic lesions on skeletal survey or whole body PET/CT other than a single lesion associated with SBP within 28 days prior to registration (PreReg); total radiation dose ranging from 4500 to 6000 cGy where RT was completed at most 90 days PreReg and no other treatment for SPB was administered PreReg; adequate laboratory values within 14 days PreReg (see Supplementary Table 1b), QTc < 470 msec, and ≤grade 2 peripheral neuropathy. Exclusion criteria included: another malignancy within 5 years PreReg; no prior PI or IMiD use, known gastrointestinal condition that could interfere with oral absorption or tolerance of study drug; cardiac arrhythmia, congestive heart failure, angina or myocardial infarction within 182 days PreReg.

Treatment schedules, trial conduct, and statistical methods

A stratified randomization procedure (with strata: age; percentage of abnormal plasma cells in the bone marrow; monoclonal protein/clonal light chains present in blood or urine; and minimal residual disease positivity) was used to assign participants in equal number to: Arm 1: IXA, LEN, DEX and ZA or Arm 2: ZA alone. Eligibility included patients with only a single lesion associated with solitary bone plasmacytoma on PET/CT and skeletal survey, and <10% bone marrow plasma cells. Treatment was given in 28-day cycles for a maximum of 6 cycles where ZA was infused on day 1 of each cycle based on creatinine clearance; 4 mg IXA was administered by mouth on days 1, 8, and 15; 15 mg LEN by mouth days 1–21; and 12 mg DEX by mouth on days 1, 8, 15, and 22. Prior to each cycle of treatment and every 3 months after treatment discontinuation until Prog-MM, patients completed a physical examination including adverse event monitoring (CTCAE v4) and laboratory studies including complete blood counts, comprehensive metabolic panel, c-reactive protein and tumor assessment including serum protein electrophoresis, serum immunofixation, immunoglobulins, and serum free light chain. PET/CT, bone marrow biopsy (BMB) and aspirate, and urine studies were completed prior to treatment start (pre-trt) and every 6 months until Prog-MM. A skeletal survey was completed pre-trt every 12 months until Prog-MM.

This study was monitored by the Alliance Data and Safety Monitoring Board twice yearly. Enrollment was terminated on August 15, 2019 due to poor enrollment having registered 10% of the planned 110 patients. Patients were followed for a maximum of 5 years post-registration. Here we report a summary of these patients’ clinical course where all eligible patients who began protocol treatment were included in the analytic cohort of the treatment arm to which they were randomized.

The primary endpoint was TTP-MM defined as the time from randomization to documentation of the first instance of criteria for multiple myeloma is met (Supplementary Table 1). TTP-MM was estimated using the Kaplan–Meier method. Patients alive without Prog-MM were censored at the start of non-protocol treatment for SPB if undertaken or date of their last disease evaluation, if not.

The trial was approved by the National Cancer Institute Central Institutional Review Board (NCI CIRB; reference A061402) and by the local Institutional review boards of participating sites that did not use the NCI CIRB. The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice Guidelines. All patients provided written informed consent prior to enrollment. Data was collected and analyzed by the Alliance Statistics and Data Management Center team and reviewed by the study chair. All reported results are based on the study database frozen on February 9, 2023. The trial was opened at 388 study locations in the US.

Results

Thirteen patients were pre-registered to this trial from November 2016 through September 2018. Two patients discontinued failing to meet registration eligibility criteria. The 11 patients registered to this study included five (4 male, 1 female) randomized to IXA-LEN-DEX-ZA aged 49–80 years (median: 70) and six (5 male, 1 female) randomized to ZA alone aged 44–74 years (median: 64). All patients received ≥40 Gy of radiation. Post-radiation bone marrow biopsy samples obtained from 9 patients underwent cytogenetics testing (FISH: 8; karyotyping: 1). No high-risk cytogenetic markers (such as t(4;14), t(14;16), t(14;20), 1q21 gain/amp, or del17p) were found. Additional patient and disease characteristics appear in Table 1.

Table 1 Patient and disease characteristics at diagnosis and post-RT and multiple myeloma defining events.

Full size table

Treatment course

All 5 patients randomized to IXA-LEN-DEX-ZA completed 6 cycles of treatment. No dose reductions were undertaken. One patient omitted 3 weeks of Cycle 1 treatment due to grade 3 periocular cellulitis. Other severe toxicities included: grade 3 hypophosphatemia (40%) and grade 3 lymphocyte count decrease (20%) (Table 2).

Table 2 Adverse events: maximum grade regardless of attribution to treatment.

Full size table

All 6 patients randomized to ZA monotherapy discontinued treatment due to completing all 6 specified treatment cycles (4 pts), Prog-MM (1 pt), or patient request (1 pt). No dose reductions were taken. Severe toxicities reported included a grade 3 INR increase (1 pt) and grade 3 white blood cell count decrease (1 pt).

Clinical outcomes

Patients have been followed until death or a median of 4.8 years post registration (PostReg). All Prog-MM involved appearance of new bone lesions and end organ damage.

Among the 5 patients randomized to IXA-LEN-DEX-ZA, 1 patient had Prog-MM 4.8 years PostReg and another patient died of unknown causes 3.3 years PostReg, with no evidence of Prog-MM at an evaluation 2 weeks prior to death. One patient chose to begin non-protocol treatment for SPB at 4.2 years PostReg due to lack of response to RT and protocol treatment. The remaining 2 patients were alive without Prog-MM 5 years PostReg. Thus, the 1- and 5- year Prog-MM rates were 0% and 33.3% (95% CI: 0–70.0%), respectively.

Among the 6 patients randomized to ZA, 1 pt had Prog-MM at 4.7 months, 1 pt had Prog-MM 4.7 months PostReg and died from complications of MM at 2.4 years PostReg; 2 pts were alive at 4.6 and 4.8 years PostReg having Prog-MM at 1.5 and 1.0 years PostReg, respectively. Three patients are alive without Prog-MM at 0.6, 2.7, and 3.7 years, respectively. Thus, the 1- and 2-year Prog-MM rates of 37.5% (95% CI: 0–68.0%) and 58.3% (95% CI: 0–85.3%), respectively,

This trial, prematurely closed due to limited accrual, could not definitively establish the role of 6 months systemic therapy in this patient population. Ultimately, this experience highlights the challenges to opening a phase 3 comparative trial in a rare disease entity that must be overcome and the well-known barriers to opening trials in important but rare clinical subsets of diseases. Because resources are limited, some study sites have adopted policies requiring the projected number of enrollments to meet or exceed a defined benchmark before a trial can open. Other sites have no formal policy but weigh the likelihood of accrual against competing trial opportunities and consequently decline to open trials for rare diseases that affect only a small proportion of patients in their catchment area. That said, these otherwise positive data underscore the need to further explore the safety and efficacy of oral adjuvant systemic treatment in patients with SPB and multicenter efforts are necessary to confirm the advantages of a well-tolerated all-oral approach and meaningfully improve real-world translation to clinical practice [16].

Data availability

De-identified patient data may be requested from the Alliance for Clinical Trials in Oncology via Datasharing@alliancenctn.org if the data are not publicly available. The formal review process includes verifying data availability and conducting contractual, regulatory, and compliance reviews of any existing agreements that may affect the project. Areas identified in the formal review are further investigated and, if warranted, require mitigation. Certain fees may be required for the preparation and transfer of the requested data and will be determined during the negotiation of the data use agreement. The investigator will be required to sign a data use agreement prior to data transfer.

References

  1. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–e548. https://doi.org/10.1016/S1470-2045(14)70442-5.

    Article  PubMed  Google Scholar 

  2. Dingli D, Kyle RA, Rajkumar SV, Nowakowski GS, Larson DR, Bida JP, et al. Immunoglobulin free light chains and solitary plasmacytoma of bone. Blood. 2006;108:1979–83. https://doi.org/10.1182/blood-2006-04-015784.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Kumar S, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Wellik L, et al. Prognostic value of angiogenesis in solitary bone plasmacytoma. Blood. 2003;101:1715–7. https://doi.org/10.1182/blood-2002-08-2441.

    Article  CAS  PubMed  Google Scholar 

  4. Paiva B, Chandia M, Vidriales MB, Colado E, Caballero-Velázquez T, Escalante F, et al. Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma. Blood. 2014;124:1300–3. https://doi.org/10.1182/blood-2014-04-567909.

    Article  CAS  PubMed  Google Scholar 

  5. Yadav U, Kumar SK, Baughn LB, Dispenzieri A, Greipp P, Ketterling R, et al. Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas. Blood. 2023;142:1871–8. https://doi.org/10.1182/blood.2023021187.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Ozsahin M, Tsang RW, Poortmans P, Belkacémi Y, Bolla M, Dinçbas FO, et al. Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients. Int J Radiat Oncol Biol Phys. 2006;64:210–7. https://doi.org/10.1016/j.ijrobp.2005.06.039.

    Article  PubMed  Google Scholar 

  7. Bolek TW, Marcus RB, Mendenhall NP. Solitary plasmacytoma of bone and soft tissue. Int J Radiat Oncol Biol Phys. 1996;36:329–33. https://doi.org/10.1016/s0360-3016(96)00334-3.

    Article  CAS  PubMed  Google Scholar 

  8. Shih LY, Dunn P, Leung WM, Chen WJ, Wang PN. Localised plasmacytomas in Taiwan: comparison between extramedullary plasmacytoma and solitary plasmacytoma of bone. Br J cancer. 1995;71:128–33. https://doi.org/10.1038/bjc.1995.26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Avilés A, Huerta-Guzmán J, Delgado S, Fernández A, Díaz-Maqueo JC. Improved outcome in solitary bone plasmacytomata with combined therapy. Hematol Oncol. 1996;14:111–7.

    Article  PubMed  Google Scholar 

  10. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002;99:4525–30.

    Article  CAS  PubMed  Google Scholar 

  11. Richardson PG, Baz R, Wang M, Jakubowiak AJ, Laubach JP, Harvey RD, et al. Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. Blood. 2014;124:1038–46. https://doi.org/10.1182/blood-2014-01-548826.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Voorhees P, Suman V, Efebera Y, Raje N, Tuchman S, Rodriguez C, et al. Alliance A061202: ixazomib, pomalidomide, and dexamethasone for patients with lenalidomide-refractory MM in first relapse. Blood Adv. 2024;8:5039–50. https://doi.org/10.1182/bloodadvances.2024013623.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Facon T, Venner CP, Bahlis NJ, Offner F, White DJ, Karlin L, et al. Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood. 2021;137:3616–28. https://doi.org/10.1182/blood.2020008787.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374:1621–34. https://doi.org/10.1056/NEJMoa1516282.

    Article  CAS  PubMed  Google Scholar 

  15. Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ, et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet. 2010;376:1989–99. https://doi.org/10.1016/S0140-6736(10)62051-X.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Richardson PG, San Miguel JF, Moreau P, Hajek R, Dimopoulos MA, Laubach JP, et al. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer J. 2018;8:109. https://doi.org/10.1038/s41408-018-0141-0.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This manuscript is the result of funding in whole or in part by the National Cancer Institute of the National Institutes of Health under Award Numbers U10CA180821 and U10CA180882 (to the Alliance for Clinical Trials in Oncology), UG1CA189824, UG1CA189956, UG1CA232760, UG1CA233178, UG1CA233180, UG1CA233191, UG1CA233193, UG1CA233290, UG1CA233329, and U10CA180888 (SWOG). https://acknowledgments.alliancefound.org. Also supported in part by Celgene and Millennium-Takeda. The manuscript is subject to the NIH Public Access Policy. Through acceptance of this federal funding, NIH has been given a right to make the Author Accepted Manuscript publicly available in PubMed Central upon the Official Date of Publication, as defined by NIH. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health

Author information

Author notes

  1. These authors contributed equally: Douglas W. Sborov, Anuj K. Mahindra, Saad Usmani, Paul G. Richardson.

Authors and Affiliations

  1. University of Utah, Huntsman Cancer Institute, Salt Lake City, UT, USA

    Douglas W. Sborov

  2. Scripps MD Anderson Cancer Center, La Jolla, CA, USA

    Anuj K. Mahindra

  3. Alliance Statistics Data and Management Center, Mayo Clinic, Rochester, MN, USA

    Vera J. Suman

  4. University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Elisabet Esteve Manasanch

  5. Mayo Clinic, Rochester, MN, USA

    Prashant Kapoor

  6. City of Hope Cancer Center, Phoenix, AZ, USA

    Tibor Kovacsovics

  7. Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Cesar Rodriguez

  8. Gundersen Health, La Crosse, WI, USA

    Benjamin Parsons

  9. Cancer Centers of Southwest Oklahoma, Oklahoma, OK, USA

    Jose Eugenio Najera

  10. Ascension Health, Southfield, MI, USA

    Lyle Goldman

  11. Alliance Protocol Operations Office, University of Chicago, Chicago, IL, USA

    Destin Carlisle, Yujia Wen, Shira H. Dinner, Ilene A. Galinsky, LeAnne Kennedy & James Omel

  12. Dana-Farber/Partners Cancer Care, Boston, MA, USA

    Ilene A. Galinsky & Paul G. Richardson

  13. Wake Forest Baptist Health/Atrium Health Wake Forest Baptist, Winston-Salem, NC, USA

    LeAnne Kennedy

  14. Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA

    Philip McCarthy

  15. Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Saad Usmani

  16. Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

    Paul G. Richardson

Authors

  1. Douglas W. Sborov
  2. Anuj K. Mahindra
  3. Vera J. Suman
  4. Elisabet Esteve Manasanch
  5. Prashant Kapoor
  6. Tibor Kovacsovics
  7. Cesar Rodriguez
  8. Benjamin Parsons
  9. Jose Eugenio Najera
  10. Lyle Goldman
  11. Destin Carlisle
  12. Yujia Wen
  13. Shira H. Dinner
  14. Ilene A. Galinsky
  15. LeAnne Kennedy
  16. James Omel
  17. Philip McCarthy
  18. Saad Usmani
  19. Paul G. Richardson

Contributions

AM, PGR, SU, and PM designed the study. All site investigators (DS, AM, EEM, PK, TK, CR, BP, JEN, LG, PM, SU, and PGR) enrolled patients and collected data. VS performed the statistical analysis. JO contributed the patient perspective to the trial design. SHD, DS, YW, IAG, and LK provided NCI regulatory support and oversight. AM and DS wrote the initial drafts. All authors reviewed and approved the final manuscript and agree to be accountable for the work.

Corresponding authors

Correspondence to Douglas W. Sborov, Saad Usmani or Paul G. Richardson.

Ethics declarations

Competing interests

DWS: Research funding: Johnson & Johnson, Regeneron; Consulting/Advisory: Johnson & Johnson, Sanofi, Pfizer, Bristol Myer Squibb, GlaxoSmithKline, Regeneron, Opna Bio, Legend Biotech. AKM: No competing financial interests. VJS: No competing financial interests. EEM: Employment/stock options: GlaxoSmithKline. PK: Honorarium: Keosys; Consulting/Advisory: BeiGene, Mustang Bio, Janssen, Pharmacyclics, X4 Pharmaceuticals, Kite, Oncopeptides, Ascentage, Angitia Bio, GlaxoSmithKline, Sanofi, Abbvie; Institutional Research Funding: Amgen, Regeneron, Bristol Myers Squibb, Loxo Pharmaceuticals, Ichnos, Karyopharm, Sanofi, Abbvie, GlaxoSmithKline. TK: Honorarium: Rigel, Servier; Consulting/Advisory: Amgen, Astellas, NeoGenomics, Rigel, Takeda. CR: Research: European Myeloma Network; Consulting/Advisory: Johnson & Johnson, Bristol Myer Squibb, Pfizer, Sanofi, Abbvie, Regeneron. BP: No competing financial interests. JEN: No competing financial interests. LG: No competing financial interests. DC: No competing financial interests. YW: No competing financial interests. SHD: No competing financial interests. IAG: No competing financial interests. LK: No competing financial interests. JO: No competing financial interests. PM: Consulting: Karyopharm, Legend Biotech, Oncopeptides, Bristol Myer Squibb; Institutional Research Funding: Bristol Myer Squibb, Celgene, Juno Therapeutics. SU: Research funding: Abbvie, Amgen, Array Biopharma, Bristol Myer Squibb, Celgene, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDx, Takeda; Consulting/Advisory: Abbvie, Amgen, Bristol Myer Squibb, Celgene, EdoPharma, Genentech, Gilead, GlaxoSmithKline, Gracell Therapeutics, Janssen, Oncopeptides, Sanofi, Seattle Genetics, SecuraBio, SkylineDX, Takeda, TeneoBio. PR: Advisory/Consulting: Bristol Myer Squibb, Celgene, GlaxoSmithKline, Karyopharm, Oncopeptides, Sanofi; Institutional Research Funding: Bristol Myer Squibb, Celgene, Karyopharm, Oncopeptides.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sborov, D.W., Mahindra, A.K., Suman, V.J. et al. Solitary plasmacytoma of bone (SPB): observations from a randomized phase III trial that evaluated the additional of adjuvant systemic treatment to zoledronic acid (ZA) after definitive radiation (alliance A061402). Blood Cancer J. 16, 203 (2026). https://doi.org/10.1038/s41408-026-01674-w

Download citation

  • Received: 17 April 2026

  • Revised: 13 September 2026

  • Accepted: 28 October 2026

  • Published: 16 November 2026

  • Version of record: 16 November 2026

  • DOI: https://doi.org/10.1038/s41408-026-01674-w

来源:Nature 健康护理主题 · nature.com